Bio-Techne Corporation
72.25USD
-0.0600 (-0.08%)
Revenue
| (USD) | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| FY | 1.1B | 1.2B | 1.2B | 1.2B | 1.3B | 1.4B |
| Q1 | 269.7M | 276.9M | 289.5M | 286.6M | 291.8M | — |
| Q2 | 271.6M | 272.6M | 297.0M | 295.9M | 308.0M | — |
| Q3 | 294.1M | 303.4M | 316.2M | 311.4M | — | — |
| Q4 | 301.3M* | 306.1M* | 317.0M* | 321.2M* | — | — |
Revenue
| (USD) | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| FY | 1.76 | 1.05 | .460 | 1.16 | 2.02 | 2.31 |
| Q1 | .550 | .310 | .210 | .240 | .431 | — |
| Q2 | .310 | .170 | .220 | .240 | .482 | — |
| Q3 | .430 | .310 | .140 | .320 | — | — |
| Q4 | .466* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| .252* |
| -.111* |
| .348* |
| — |
| — |